Incretins and MASLD: What 24 Trials Found

A 2026 meta-analysis of 24 randomized trials found that incretin therapies improved several liver measures in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Compared with placebo, the pooled results favored incretin treatment for the liver enzymes ALT and AST and for resolution of steatohepatitis, the inflammatory form of fatty liver disease. The same analysis did not show a statistically significant improvement in fibrosis regression^[1]. That distinction matters. Better enzymes and less inflammation are encouraging, but they do not prove that liver scarring has reversed or that long-term liver complications will fall.

The review covered several GLP-1 receptor agonists as well as newer dual agonists. Its 2,158 participants received medicines including liraglutide, exenatide, dulaglutide, semaglutide and tirzepatide, plus investigational agents. The findings therefore describe a mixed treatment class, not a clean head-to-head test of any two drugs^[1].

What the researchers pooled

The authors searched PubMed, Scopus, Embase and ClinicalTrials.gov through 22 August 2025. Eligible randomized controlled trials enrolled adults with MASLD or biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). They compared an incretin medicine with placebo, an oral glucose-lowering medicine or insulin. Outcomes included liver enzymes, liver fat measured by imaging, non-invasive fibrosis markers, biopsy endpoints and adverse events^[1].

The evidence was varied. Some trials required a liver biopsy, while others used ultrasound, MRI or elastography. Treatment lasted a median of 24 weeks, but individual trials differed in duration, medicine, comparator and participant profile. The review used separate random-effects analyses for placebo, insulin and oral-drug comparisons because combining those control groups would blur clinically different questions^[1].

The treatment mix is also important when reading this as a peptide trial update. Older GLP-1 medicines supplied much of the evidence, while the included dual-agonist data came from a smaller group of studies. One was NCT04166773, a 190-participant Phase 2 trial that compared three tirzepatide dose groups with placebo for 52 weeks^[2]. Results from the pooled class should not be assigned automatically to a single tirzepatide regimen or used to predict what another GLP-1 medicine will do for one patient. The analysis is best read as a map of which liver outcomes now have a signal and which still lack convincing evidence.

Liver enzymes improved versus placebo

Across 12 placebo-controlled trials with 1,466 participants, incretin therapies reduced ALT with a standardized mean difference of -0.46 (95% confidence interval -0.67 to -0.25) and AST by -0.41 (-0.66 to -0.17). These are standardized effects rather than changes in familiar laboratory units, because the studies reported their results in different ways. Both pooled estimates were statistically significant^[1].

The imaging result was less tidy. Six placebo-controlled trials with 209 participants produced a standardized mean difference in liver fat of -0.55, but its confidence interval ran from -1.38 to 0.27 and crossed zero. Statistical heterogeneity was high at 86.7%, which means the trial results varied substantially. In three studies comparing incretin therapies with insulin, liver fat favored incretins by -0.62 (-0.92 to -0.32), but that is a different clinical comparison^[1].

Inflammation improved, fibrosis did not

Five trials with 1,762 participants reported steatohepatitis resolution. The pooled relative risk was 1.25 (1.16 to 1.34), meaning resolution was more common with incretin therapy than with control. The placebo subgroup produced a similar estimate. By contrast, four trials with 1,479 participants found no significant improvement in fibrosis regression: relative risk 1.08 (0.97 to 1.20)^[1].

Non-invasive fibrosis measures also need a careful read. Liver stiffness by FibroScan and the ELF blood score favored incretin therapy versus placebo, but both analyses had very high heterogeneity. FIB-4, another blood-based fibrosis index, did not improve significantly in the placebo or insulin comparisons. These markers can help track risk, but they are not interchangeable with biopsy-proven fibrosis regression^[1].

Safety and the diabetes subgroup

Gastrointestinal adverse events were more frequent with incretin therapies. Across 17 trials, the pooled relative risk was 1.13 (1.08 to 1.19). The review found no increase in serious adverse events, hypoglycemia or drug-related pancreatitis across its pooled analyses. These results summarize trial populations and follow-up periods; they do not replace the safety information or contraindications attached to an individual prescription^[1].

Exploratory analyses suggested larger effects on some liver outcomes among participants with diabetes. Those subgroup results rested on few eligible studies, and some endpoints came from a single trial. They should not be read as proof that diabetes status determines who will benefit. Anyone using tirzepatide under clinical care or another incretin should discuss liver findings in the context of the approved indication and their own medical history.

What this readout cannot answer

This meta-analysis supports a narrow conclusion: incretin therapies can improve liver enzymes and the chance of steatohepatitis resolution in selected trial populations, while evidence for actual fibrosis regression remains inconclusive. It cannot tell us whether one incretin is best for MASLD. The drug mix was broad, follow-up was often short for a slowly changing process such as fibrosis, and the authors could not run useful analyses by sex or ethnicity^[1].

Longer trials with standardized imaging and biopsy outcomes are needed to show whether early changes lead to fewer cases of cirrhosis, liver cancer or transplantation. Until then, improvements in ALT, AST or liver fat are signals of biological effect, not proof of long-term liver protection. Our semaglutide evidence page covers the wider evidence and safety context.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.